Non-profit drug research confronts the distance from discovery to access
Published on 12 November 2026 at 02:29 GMT
By Editorial Team SDG3
A promising compound is not yet a treatment available to a patient. Between research and routine use lie clinical evidence, authorisation, production and delivery. The Drugs for Neglected Diseases initiative (DNDi) organises non-profit research around patients whose needs it describes as neglected by conventional drug development. Its model brings attention to how priorities are chosen as well as how medicines reach the people for whom they are developed.
Founded in 2003, DNDi emerged from collaboration between public research institutions and Médecins Sans Frontières, with participation from the World Health Organization's Special Programme for Research and Training in Tropical Diseases. It describes itself as a not-for-profit research organisation developing treatments for neglected patients. Its work concerns unmet medical needs rather than a guarantee that every research project will produce a treatment.
The organisation’s partnership model connects public, private, academic and philanthropic expertise. It presents patient needs, scientific independence and the sharing of knowledge as guiding principles. These are institutional commitments about how research is organised. They do not eliminate scientific uncertainty or establish that every candidate in a development portfolio will become an authorised treatment.
Neglect has several dimensions
The World Health Organization (WHO) describes neglected tropical diseases as a varied group of conditions associated with health, social and economic consequences. They are concentrated mainly in impoverished communities, although some have a wider geographical distribution. This context explains why research priorities concern more than the size of a technically addressable disease category.
A medicine can exist while remaining difficult to use in a particular setting. The features of a product, the services available to administer it and the cost of delivery are separate aspects of access. Research aimed at patients therefore involves questions about the circumstances in which a treatment would be used, rather than only whether a molecule shows activity in a laboratory.
DNDi says it begins with medical needs and follows work through discovery, development and access. That approach links the intended characteristics of a treatment to its research pathway. A target product profile describes an aim for development; it is not a clinical result. A completed study provides evidence within its design and population, rather than an automatic answer for every patient group.
The distinctions continue after research. Regulatory authorisation concerns a particular product and indication in a jurisdiction. Availability concerns whether a product can actually be obtained. Affordability concerns what patients and health systems pay. A favourable result in one category does not establish that the remaining categories have been resolved.
Partnership does not remove uncertainty
A collaborative model distributes work across institutions with different roles. Discovery, clinical research, manufacturing and programme delivery can involve different partners. This can broaden the expertise involved without making their responsibilities interchangeable. A research organisation coordinating development is not necessarily the manufacturer supplying every market or the provider treating every patient.
The organisation also advocates open and transparent research, including the sharing of data, knowledge and costs. That is an attributed policy position. Openness can be examined through what information is actually available and on what terms. The existence of a commitment does not by itself establish the completeness of a dataset or the availability of every contractual detail.
Evidence about impact similarly depends on the stage measured. The number of partnerships or research projects records activity. An authorised medicine records a development milestone. Patient treatment records use. Health outcomes concern what happens after treatment. These can all form part of the same development history, but they answer different questions about the contribution of a research model.
The connection to SDG 3 (good health and well-being) concerns neglected diseases and access to medicines. The goal situates research within a wider health agenda, while leaving the practical route from a candidate to a delivered treatment open to examination. Scientific progress and equitable access are related objectives rather than identical measures.
A portfolio also contains projects at different stages. Listing a candidate under research does not describe it as ready for prescription. A development milestone is tied to a particular treatment and indication, while the wider organisation’s mission concerns a broader population. Keeping that level of detail visible prevents a research pipeline from being read as a list of medicines already available in routine care.
The model presented by DNDi offers a way to organise research around neglected needs without treating commercial demand as the sole expression of medical priority. Its results remain assessable at each stage: the evidence generated, the products authorised and the treatments people can obtain. That sequence keeps the public-interest focus on patients while preserving the difference between a research ambition and an established clinical or access outcome.
Written by a human author, edited with AI assistance.
Further information:
• DNDi who we are. Documents its founding and non-profit research purpose.
• DNDi how we work. Explains needs-led partnerships and its stated open research principles.
• WHO neglected tropical diseases. Provides context on the conditions and their social and health consequences.
• United Nations Goal 3. Supports the connection to neglected diseases and access to medicines.
